{"analyses":[{"ciPctValue":"95","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","statisticalMethod":"Chi-squared","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"33"}],"units":"Participants"}],"description":"Response is defined as follows:\n\n* CR: Complete disappearance of M-protein from serum \\& urine on immunofixation, \\<5% plasma cells in bone marrow (BM)\n* VGPR: \\>=90% reduction in serum M-component; Urine M-Component \\<100 mg per 24 hours; \\<=5% plasma cells in BM\n* PR: \\>= 50% reduction in serum M-Component and/or Urine M-Component \\>= 90% reduction or \\<200 mg per 24 hours; or \\>= 50% decrease in difference between involved and uninvolved FLC levels","groups":[{"description":"Thalidomide (Thal) + Zolendronic acid (ZLD)","id":"OG000","title":"Arm I: Thal/ZLD"},{"description":"Zoledronic acid (ZLD)","id":"OG001","title":"Arm II: ZLD"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"12 months","title":"Number of Participants With a Confirmed Response (Complete Response [CR], Very Good Partial Response [VGPR] or Partial Response [PR]) on Two Consecutive Evaluations at Least 2 Weeks Apart in the First 12 Months of Treatment","type":"SECONDARY","unitOfMeasure":"participants"}